Known targets — ChEMBL curated mechanism
PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Sotrastaurin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH known ✓ | P24723 | 20/20 | 1.00 |
| ▸ | PRKCQ known ✓ | Q04759 | 20/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 20/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 19/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 18/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 17/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 2/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 1.00 |
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sotrastaurin SCHEMBL29526075 | 1.00 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29364923 | 1.00 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL3846239 | 0.96 | PRKCH (0.93) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29412439 | 0.96 | PRKCH (0.93) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL2493700 | 0.89 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL31647944 | 0.89 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL1994301 | 0.88 | PRKCH (0.78) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL1991835 | 0.86 | PRKCH (0.76) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL4905416 | 0.86 | PRKCH (0.76) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL19663760 | 0.85 | PRKCH (0.74) | PRKCHPRKCQPRKCDPRKCAPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414672-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING NEURAL PRECURSOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS | SBIOMEDICS (KR) | 2023-12-28 | — | — | US | claimed |
| EP-4241777-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING NEURAL PRECURSOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS | SBIOMEDICS (KR) | 2023-09-13 | — | — | EP | claimed |
| CN-116507347-A | Pharmaceutical composition for treating degenerative brain diseases comprising neural precursor cells derived from pluripotent stem cells | S生物医药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022098110-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING NEURAL PRECURSOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS | (주) 에스바이오메딕스 | 2022-05-12 | — | — | WO | claimed |
| US-20210395680-A1 | COMPOSITION AND KIT FOR DIFFERENTIATION OF STEM CELLS INTO NEURAL PROGENITOR CELLS, AND METHOD USING SAME | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2021-12-23 | — | — | US | claimed |
| US-10365268-B2 | Methods for identifying modulators of membrane potentials in bipolar disorder and attention deficit hyperactivity disorder | PSYCHNOSTICS, LLC (US) | 2019-07-30 | — | — | US | claimed |
| EP-3334426-A2 | MDM2 INHIBITORS FOR TREATING UVEAL MELANOMA | Novartis AG (CH) | 2018-06-20 | — | — | EP | claimed |
| EP-2925366-B1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | claimed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | claimed |
| EP-3233918-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-10-25 | — | — | EP | claimed |
| US-20090131450-A1 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS | WAGNER JURGEN | 2009-05-21 | — | — | US | claimed |
| EP-2056831-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | Novartis AG (CH) | 2009-05-13 | — | — | EP | claimed |
| EP-2037926-A1 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS | Novartis AG (CH) | 2009-03-25 | — | — | EP | claimed |
| WO-2008112479-A1 | SALTS OF 3- (1H-IND0L-3-YL) -4- [2- (4-METHYL-PIPERAZIN-I-YL) -QUINAZOLIN-4-YL] -PYRROLE-2, 5-DI ONE | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | claimed |
| WO-2008073770-A1 | USE OF PKC INHIBITORS IN TRANSPLANTATION | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| WO-2008024734-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| WO-2008000484-A1 | VERFAHREN ZUR HERSTELLUNG VON PENTAMETHYLEN-1,5-DIISOCYANAT | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | claimed |
| US-20070142401-A1 | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation | NOVARTIS AG (CH) | 2007-06-21 | — | — | US | claimed |
| EP-1682103-A1 | INDOLYL-PYRROLEDIONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND VASCULAR DISORDERS RELATED TO BETA-AMYLOID GENERATION AND/OR AGGREGATION | Novartis AG (CH) | 2006-07-26 | — | — | EP | claimed |
| WO-2005039549-A1 | INDOLYL-PYRROLEDIONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND VASCULAR DISORDERS RELATED TO BETA-AMYLOID GENERATION AND/OR AGGREGATION | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142401-A1 | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation | PRKCH, PRKCD, PRKCZ | PRKCH 1/4885PRKCQ 7/4885PRKCD 2/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | PRKCH 1392/4885PRKCQ 1649/4885PRKCD 2399/4885 |
| US-20090131450-A1 | USE OF PKC INHIBITORS IN DIABETIC COMPLICATIONS | PRKCH, PRKCA, PRKCB | PRKCH 1/4885PRKCQ 8/4885PRKCD 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.